1. Home
  2. DLPN vs BCDA Comparison

DLPN vs BCDA Comparison

Compare DLPN & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DLPN
  • BCDA
  • Stock Information
  • Founded
  • DLPN 1996
  • BCDA N/A
  • Country
  • DLPN United States
  • BCDA United States
  • Employees
  • DLPN N/A
  • BCDA N/A
  • Industry
  • DLPN Other Consumer Services
  • BCDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • DLPN Consumer Discretionary
  • BCDA Health Care
  • Exchange
  • DLPN Nasdaq
  • BCDA Nasdaq
  • Market Cap
  • DLPN 12.6M
  • BCDA 10.1M
  • IPO Year
  • DLPN N/A
  • BCDA N/A
  • Fundamental
  • Price
  • DLPN $1.12
  • BCDA $2.13
  • Analyst Decision
  • DLPN Strong Buy
  • BCDA Strong Buy
  • Analyst Count
  • DLPN 1
  • BCDA 1
  • Target Price
  • DLPN $5.00
  • BCDA $25.00
  • AVG Volume (30 Days)
  • DLPN 50.2K
  • BCDA 83.8K
  • Earning Date
  • DLPN 08-13-2025
  • BCDA 08-12-2025
  • Dividend Yield
  • DLPN N/A
  • BCDA N/A
  • EPS Growth
  • DLPN N/A
  • BCDA N/A
  • EPS
  • DLPN N/A
  • BCDA N/A
  • Revenue
  • DLPN $48,618,803.00
  • BCDA $3,000.00
  • Revenue This Year
  • DLPN $6.57
  • BCDA N/A
  • Revenue Next Year
  • DLPN $18.10
  • BCDA N/A
  • P/E Ratio
  • DLPN N/A
  • BCDA N/A
  • Revenue Growth
  • DLPN 0.31
  • BCDA N/A
  • 52 Week Low
  • DLPN $0.75
  • BCDA $1.63
  • 52 Week High
  • DLPN $1.74
  • BCDA $4.66
  • Technical
  • Relative Strength Index (RSI)
  • DLPN 41.03
  • BCDA 43.00
  • Support Level
  • DLPN $1.18
  • BCDA $2.22
  • Resistance Level
  • DLPN $1.42
  • BCDA $2.42
  • Average True Range (ATR)
  • DLPN 0.11
  • BCDA 0.12
  • MACD
  • DLPN -0.02
  • BCDA -0.02
  • Stochastic Oscillator
  • DLPN 21.43
  • BCDA 20.53

About DLPN Dolphin Entertainment Inc.

Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: